Comment on

• Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

  Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Liu L, Pais P, Diaz R, Xavier D, Sliwa K, Dans A, Avezum A, Piegas LS, Keltai K, Keltai M, Chazova I, Peters RJ, Held C, Yusoff K, Lewis BS, Jansky P, Parkhomenko A, Khunti K, Toff WD, Reid CM, Varigos J, Leiter LA, Molina DI, McKelvie R, Pogue J, Wilkinson J, Jung H, Dagenais G, Yusuf S; HOPE-3 Investigators. Lonn EM, et al. N Engl J Med. 2016 May 26;374(21):2009-20. doi: 10.1056/NEJMoa1600175. Epub 2016 Apr 2. N Engl J Med. 2016. PMID: 27041480 Clinical Trial.
• Blood-Pressure and Cholesterol Lowering in the HOPE-3 Trial.

  Emrich IE, Schulz DM, Heine GH. Emrich IE, et al. N Engl J Med. 2016 Sep 22;375(12):1190. doi: 10.1056/NEJMc1608916. N Engl J Med. 2016. PMID: 27653573 No abstract available.
• Blood-Pressure and Cholesterol Lowering in the HOPE-3 Trial.

  Strauss MH, Hall AS. Strauss MH, et al. N Engl J Med. 2016 Sep 22;375(12):1191. doi: 10.1056/NEJMc1608916. N Engl J Med. 2016. PMID: 27653574 No abstract available.
• Blood-Pressure and Cholesterol Lowering in the HOPE-3 Trial.

  Jeong YH, Ahn JH, Smith SC Jr. Jeong YH, et al. N Engl J Med. 2016 Sep 22;375(12):1191-2. doi: 10.1056/NEJMc1608916. N Engl J Med. 2016. PMID: 27653575 No abstract available.
• Blood-Pressure and Cholesterol Lowering in the HOPE-3 Trial.

  Mascitelli L, Goldstein MR. Mascitelli L, et al. N Engl J Med. 2016 Sep 22;375(12):1192-3. doi: 10.1056/NEJMc1608916. N Engl J Med. 2016. PMID: 27653576 No abstract available.